

## lt's Wholecare.

Updated: 07/2021 PARP Approved: 07/2021

## Prior Authorization Criteria Givlaari (givosiran)

All requests for Givlaari (givosiran) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a <u>diagnosis</u> of acute hepatic porphyria (AHP) and the following criteria is met:

- Member must be 18 years of age or older
- Must be prescribed by or in consultation with a provider who specializes in porphyria (i.e. hematologist, hepatologist, gastroenterologist)
- Member must have active disease defined as having at least 2 documented porphyria attacks requiring hospitalization, urgent care visits, or IV hemin administration within the last 6 months.
- Documentation the members has had elevated urinary or plasma porphobilinogen (PBG) or aminolevulinic acid (ALA) levels with the past year (reference range must be provided)
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Initial Duration of Approval: 6 months
- Reauthorization criteria
  - o Documentation from the prescriber indicating stabilization or improvement in the member's condition since starting the medication.
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



## lt's Wholecare.

Updated: 07/2021 PARP Approved: 07/2021

## GIVLAARI (GIVOSIRAN) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation

as applicable to Gateway Health <sup>SM</sup> Pharmacy Services. FAX: (888) 245-2049				
If needed, you may call to speak to a Pharmacy Services Representative.				
PHONE: (800) 392-1147 Monday through Friday 8:30am to 5:00pm				
PROVIDER INFORMATION				
Requesting Provider:		NPI:		
Provider Specialty:		Office Contact:		
Office Address:		Office Phone:		
Office Fax:				
MEMBER INFORMATION  Member Name: DOB:				
Gateway ID:		- '	Member weight:pounds orkg	
REQUESTED DRUG INFORMATION				
			Strength:	
Directions:		Quantity:	Refills:	
Is the member currently receiving re-	quested medication? Yes		Date Medication Initiated:	
Billing Information				
This medication will be billed:   at a pharmacy OR				
medically (if medically please provide a JCODE:				
Place of Service: Hospital Provider's office Member's home Other				
Place of Service Information				
Name: NPI:				
Address:		Phone:		
MEDICAL HISTORY (Complete for ALL requests)				
Diagnosis: Acute Hepatic Porphyria (AHP) Other: ICD-10 Code:				
Has the member had 2 or more porphyria attacks in the last 6 months that required at least one of the following: a hospitalization, an				
urgent care visit, or IV hemin administration?				
Please provide one of the following				
Urinary or plasma porphobilinogen (PBG): refe				
		rence range:	date taken:	
CURRENT or PREVIOUS THERAPY				
Medication Name	Strength/ Frequency	Dates of Thera	py Status (Discontinued & Why/Current)	
REAUTHORIZATION				
Has the member experienced a stabilization or improvement with treatment?  Yes No				
Please describe:				
SUPPORTING INFORMATION or CLINICAL RATIONALE				
Duccoulting Duccid	on Cianatura		Doto	
Prescribing Provide	er Signature		Date	